Summit Therapeutics Inc. - 8-K Filing
On June 2, 2026, Summit Therapeutics Inc.'s Audit Committee and independent directors approved one or more affiliates to purchase shares of the company's common stock under an at-the-market offering with JP Morgan Securities LLC as Sales Agent. Additionally, Co-CEOs Robert Duggan and Dr. Mahkam Zanganeh, along with COO/CFO Manmeet Soni, are likely to purchase shares in the near term through this program.
Tickers: $SMMT